15.10
Personalized Neoantigen Vaccines Show Feasibility in Ovarian Cancer Trial
A phase 1 trial found that personalized neoantigen vaccines combined with PD-1 blockade were feasible in high-grade serous ovarian cancer and produced tumor-specific immune responses in man…